McAndrews

About

  • The Orange Book blog team are a group of attorneys with McAndrews, Held and Malloy, which is a full-service IP firm representing both brands and generics in various aspects of IP law. This blog does not provide legal advice. If you are seeking legal advice, please contact the author directly.

Disclaimer

  • Orange Book Blog is published for informational purposes only; it contains no legal advice whatsoever. Publication of Orange Book Blog does not create an attorney-client relationship. Orange Book Blog is not edited by McAndrews, Held & Malloy, Ltd. ("MHM") or its clients. The views expressed are solely those of the authors, and may not reflect the views of MHM or its clients. No part of Orange Book Blog--whether information, commentary, or other--may be attributed to MHM or its clients. MHM represents many companies in the pharmaceutical and biotechnology industries, and therefore Orange Book Blog may occasionally report on news that relates to MHM clients. Orange Book Blog will always strive to be unbiased. All information on Orange Book Blog should be double-checked for its accuracy and current applicability.

« The America Invents Act: a Three-Page Guide and Detailed Presentation | Main | CPhI "Pharma IPR India 2012" Conference, Mumbai, January 31 to February 2, 2012 »

October 21, 2011

ACI "Advanced Forum on Biotech Patents" Conference, Boston, Nov. 30 - Dec. 1

American Conference Institute will be holding its 13th Advanced Forum on Biotech Patents conference at the Omni Parker House hotel in Boston, MA, November 30th to December 1st.  ACI subtitles this conference, "practical strategies for prosecuting and litigating biotech patents in a rapidly shifting legal environment."

The agenda includes many presentations that will prove valuable:

  • Protection vs. Exploitation: Preparing for the Next Chapter in the Development of Biosimilars
  • Examining the Potential Effect of Patent Reform on PTO Practices and its Impact on Biotech Patents
  • Preparing for a Radical Overhaul of the U.S. Patent System: The Impact of Reform on Biotech Patent Strategies
  • Examining 35 U.S.C. 101 Subject Matter Patentability in the Wake of Myriad and Prometheus
  • Microsoft v. i4i and Stanford v. Roche: Understanding Their Collective Implications for the Biotechnology Industry
  • Confronting the Written Description Requirement Post-Centocor and Evaluating its Impact on Biotech Patent Practices
  • The Emergence of the New Obviousness Standard and its Impact on Biotech Patenting: Taking a Closer Look at Obviousness-Type Double Patenting
  • Inequitable Conduct Following Therasense: Assessing its Significance for Biotech Patent Litigation
  • International Filing: Strategic Considerations and Advanced Tactics for Patenting Biotech Inventions Abroad
  • Analyzing and Resolving the Difficulties of Claiming Joint Infringement After Akamai and McKesson
  • Creating Favorable Patent Tactics in Developing Countries

In addition, ACI is offering an option pre-conference session in the morning of November 30th that will feature two Supervisory Patent Examiners from teh USPTO:  "Integrating Changes at the PTO into Biotech Patent Practices."  ACI is also offering optional post-conference Master Class on December 2nd:  "Successful and Practical Strategies for Patenting Antibodies."

For more information or to register, please visit the conference website.  To receive a $200 discount on registration fees, use discount code OBB 200.

Posted by in Conferences |

Comments

The comments to this entry are closed.